Fallah J, Agrawal S, Gittleman H, Fiero MH, et al. FDA Approval Summary: lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 2022 Dec 5:CCR-22-2875. doi: 10.1158/1078-0432.CCR-22-2875.
PMID: 36469000